Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.62 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.55 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.48 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 8/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455498 | 1.00 | FOLH1 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL1455499 | 1.00 | FOLH1 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| Ammonia Solution, Strong SCHEMBL4293159 | 0.98 | FOLH1 (0.60) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| Ammonia Solution, Strong SCHEMBL4293156 | 0.98 | FOLH1 (0.60) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL27860271 | 0.94 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL2114733 | 0.94 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL2114736 | 0.94 | FOLH1 (0.54) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL30964327 | 0.93 | SLC15A2 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL30371073 | 0.93 | SLC15A2 (0.62) | FOLH1SLC15A2SLC6A5GNPATGSR | |
| SCHEMBL29532146 | 0.89 | SLC15A2 (0.58) | FOLH1SLC15A2SLC6A5GNPATCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896407-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| WO-2006137782-A1 | NOVEL 2-AZETIDINONE DERIVATIVES AND THEIR USE AS CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF HYPERLIPIDAEMIA | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | WO | claimed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | claimed |
| CN-1122577-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | DU PONT MERCK PHARMA (US) | 1996-05-15 | — | — | CN | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4696699-A1 | ? OPIOID RECEPTOR AGONIST AND USE THEREOF | Chengdu Aoda Biotechnology Co., Ltd. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4653017-A1 | ANTIBODY-DRUG CONJUGATE AND USE THEREOF | Tyligand Bioscience (Shanghai) Limited (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | disclosed |
| CN-120019075-A | Antibody drug conjugates targeting C-MET and methods of use | 酵活英属哥伦比亚有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118994397-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2023012282-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2023-02-09 | — | — | WO | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
| WO-2022228422-A1 | BISPECIFIC ANTIBODY-DRUG CONJUGATE | 轩竹生物科技股份有限公司 | 2022-11-03 | — | — | WO | disclosed |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | ASTRAZENECA AB (SE) | 2010-04-22 | — | — | US | disclosed |
| EP-0995761-A2 | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | Dupont Pharmaceuticals Company (US) | 2000-04-26 | — | — | EP | disclosed |
| CN-1122577-A | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders | DU PONT MERCK PHARMA (US) | 1996-05-15 | — | — | CN | disclosed |
| EP-0677061-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995010534-A1 | POLYPEPTIDE AND ANTI-HIV AGENT PREPARED THEREFROM | SEIKAGAKU CORPORATION (JP) | 1995-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | FOLH1 48/4885SLC15A2 1099/4885SLC6A5 1310/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | FOLH1 21/4885SLC15A2 1293/4885SLC6A5 3163/4885 |
| US-20100099657-A2 | Diphenylazetidinone Derivatives Possessing Cholesterol Absorption Inhibitory Activity | CYP46A1, CYP51A1, DHCR7 | FOLH1 1436/4885SLC15A2 588/4885SLC6A5 870/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FOLH1 1934/4885SLC15A2 1999/4885SLC6A5 1589/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | FOLH1 6/4885SLC15A2 301/4885SLC6A5 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.